Great post 007. Severely undervalued is the key note, and completely agree here.The current trading multiples on both EBIT (4.9x) and NPAT (4.6x) basis (post dilution) make it well worth the risk.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025